Choice of initial therapy for hypertension

JAMA

Volumn 275, Issue 20, 1996, Pages 1577-1580

  Kaplan, Norman M ^a,b   Gifford, Ray W ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FELODIPINE; FUROSEMIDE; GUANADREL; INDAPAMIDE; METHYLDOPA; METOLAZONE; NADOLOL; PINDOLOL; PRAZOSIN; PROPRANOLOL; RESERPINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNINDEXED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CLINICAL PROTOCOL; DRUG EFFICACY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0029971915     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.20.1577     Document Type: Review

References (30)

1. Reeves RA. Does this patient have hypertension? how to measure blood pressure. JAMA. 1995;273: 1211-1218.
2. Pierdomenico SD, Mezzetti A, Lapenna D, et al. 'White-coat' hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Eur Heart J. 1995;16:692-697.
3. Verdecchia P, Poreellati C, Schillaci G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
4. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
5. Kaplan NM. Treatment of hypertension: drug therapy. In: Kaplan NM. Clinical Hypertension, 6th ed. Baltimore, Md: Williams & Wilkins; 1994:191-280.
6. Applegate WB, Phillips HL, Schnaper H, et al. A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch Intern Med. 1991;151:1817-1823.
7. Silagy CA, McNeil JJ, McGrath BP. Crossover comparison of atenolol, enalapril, hydrochlorothiazide and isradipine for isolated systolic systemic hypertension. Am J Cardiol. 1992;70:1299-1305.
8. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of mild hypertension study: final results. JAMA. 1993;270:713-724.
9. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. N Engl J Med. 1993;328:914-921.
10. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension: treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med. 1994;154: 1461-1468.
11. Burnier M, Waeber B, Brunner HR. First-line pharmacological treatment of hypertension. J Intern Med. 1992;232:381-388.
12. Gifford RW Jr. Resistant hypertension: introduction and definitions. Hypertension. 1989;(suppl II):II65-II66.
13. Maheux P, Facchini F, Jeppesen J, et al. Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension: comparison between non-diabetic individuals and patients with non-insulin-dependent diabetes mellitus. Am J Hypertens. 1994; 7:416-424.
14. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension. J Urol 1995;154:110-115.
15. Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction. Prog Cardiomsc Dis. 1985;27:335-371.
16. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
17. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
18. Wright JT Jr. The antihypertensive and lipid lowering heart attack prevention trial (ALLHAT). Am J Hypertens. 1995;8:27A. Abstract.
19. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med. 1992; 327:669-677.
20. Lewis EJ, Hunsicker LG, Bain RP, et al, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
21. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan. N Engl J Med. 1995;333:1572.
22. Swales JD. Guidelines on guidelines. J Hypertension. 1993;11:899-903.
23. Ogilvie RI, Burgess ED, Cusson JR, Feldman RD, Leiter LA, Myers MG. Report of the Canadian Hypertension Society Consensus Conference, 3: pharmacologic treatment of essential hypertension. Can Med Assoc J. 1993;149:575-584.
24. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ. 1993;306:983-987.
25. Hypertension Guidelines Committee, South Australian Faculty, Royal Australian College of General Practitioners. Hypertension: Diagnosis, Treatment and Maintenance: Guidelines Endorsed by the High Blood Pressure Research Council of Australia. Adelaide: South Australian Faculty, Royal Australian College of General Practitioners; 1991.
26. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ. 1993;307:107-110.
27. Subcommittee of WHO/ISH Mild Hypertension Liaison Committee. Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. BMJ. 1993;307;1541-1546.
28. Tobian L, Brunner HR, Cohn JN, et al. Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V consensus guidelines. Am J Hypertens. 1994;7:859-872.
29. Carter BL, Kriesel HT, Steinkraus L, Knudson R. Antihypertensive drug-prescribing patterns of internists and family physicians. J Fam Pract. 1989; 29:257-262.
30. Ribacke M. Treatment preferences, return visit planning and factors affecting hypertension practice amongst general practitioners and internal medicine specialists (the General Practitioner Hypertension Practice Study). J Intern Med. 1995;237:473-478.